Buy this Article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MS, RN

Abstract

* Two new antibiotics, tedizolid (Sivextro) and oritavancin (Orbactiv), were recently approved to treat serious skin and skin-structure infections.

 

* Tedizolid is given for six days either orally or intravenously. The most common adverse effects are nausea, headache, diarrhea, vomiting, and dizziness.

 

* Oritavancin is given as a single IV dose. The most common adverse effects are headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea.